Tony Collins Appointed CFO of Xenter

Former Zimmer Biomet Group CFO

What To Know

  • “We believe that medical data should be owned by patients, that ease of accessibility to medical data is of vital importance to both physicians and patients, and that new global platforms are needed for the collection and management of medical data,” continued Mr.
  • Xenter continues to plan for rapid expansion and delivering on its commitment to launch a global platform of wireless medical devices that transmit Physical Intelligence data into a global healthcare cloud.

Following the formation of the Xenter Therapeutics and Xenter Medical Technologies business units, Xenter, Inc. (XenterMD.com), the first purpose-built medical device-data-drug technologies company, today announced the appointment of Tony Collins as Chief Financial Officer.

Xenter continues to plan for rapid expansion and delivering on its commitment to launch a global platform of wireless medical devices that transmit Physical Intelligence data into a global healthcare cloud.

Xenter’s global healthcare cloud will create a healthcare data ecosystem that leverages digital biomarkers for therapeutic drug development and enable the deployment of AI analytics utilizing PI data to improve medical procedures.

Tony Collins served as Group Chief Financial Officer at Zimmer Biomet since 2019 where he was responsible for all strategic and financial planning, business development, accounting, and internal controls for over $8B in revenues across all global business units. Additionally, Collins held numerous other financial leadership positions at Zimmer Biomet, including Vice President, Finance, Corporate Controller and Chief Accounting Officer and Vice President Finance for Global Operations and Supply Chain. Prior to Zimmer Biomet, Collins held several executive leadership positions with Guidant/Boston Scientific, including Chief Financial Officer of Guidant Japan.

“I am very excited to join Xenter’s fast-growing and innovative executive team,” Collins said. “I believe Xenter will transform interventional medicine by developing a platform using smart technologies, ultimately giving patients control of their medical data. With this new role, I am eager to use my industry knowledge and experience to further guide and develop Xenter’s Data, Therapeutic, and Medical Technologies teams.”

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer. He understands how to build great companies that have tremendous business acumen, accountability, and financial operations that are best in class. I’m looking forward to working closely with Tony as we tackle the significant goals we have set at Xenter.”

“We believe that medical data should be owned by patients, that ease of accessibility to medical data is of vital importance to both physicians and patients, and that new global platforms are needed for the collection and management of medical data,” continued Mr. Linder. “I will continue to drive this message to our employees, physicians, and patients globally and work hard to realize these objectives.”

Other Executives In the News

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Executives on the Move

“Adding Michael to the Avation leadership team is our next step in launching Vivally,” said Jill Schiaparelli, founder and CEO of Avation Medical. “Patients have been crystal clear that they want a surgical-free, non-invasive treatment option for their OAB symptoms. Our focus now is to ensure that Vivally is easily accessible to the 46 million patients suffering from OAB in this country.”
Dennis has an extraordinary depth of knowledge and is highly respected in the obesity field; I could not imagine anyone more perfect to lead our company,” said Jeff Arnold, Chairman and a Director at Xeno Biosciences since 2017.
Peter Eckes offers more than a 30-year career in the agricultural industry, and provides a unique appreciation for what it takes to bring innovation to the modern agriculture marketplace at scale without losing sight of farmer and consumer needs.